Quantification of normal bone and osseous metastases in castration-resistant prostate cancer using SPECT/CT with xSPECT Quant: prospective imaging sub-study of a phase 2 clinical trial investigating the combination of pembrolizumab plus radium-223 compared to radium-223 alone
La radiologia medica · 2024
DOI: 10.1007/s11547-024-01931-7 ↗Kurz gefasst
Klinische Studie (Phase II) in der Zeitschrift La radiologia medica, 2024. Verfasst von Matthew S Robertson und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Imaging, Dana-Farber Cancer Institute, Department of Radiology Brigham and Women's Hospital, Boston, MA, 02115, USA. mrobertson@bwh.har…. Hauptthemen laut MEDLINE: Bone Neoplasms, Prostatic Neoplasms, Castration-Resistant, Radium, Single Photon Emission Computed Tomography Computed Tomography. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 22 Literaturangaben.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Imaging, Dana-Farber Cancer Institute, Department of Radiology Brigham and Women's Hospital, Boston, MA, 02115, USA. mrobertson@bwh.harvard.edu.
- Division of Biostatistics, Department of Data Science, Dana-Farber Cancer Institute, Boston, MA, USA.
- Department of Imaging, Dana-Farber Cancer Institute, Department of Radiology Brigham and Women's Hospital, Boston, MA, 02115, USA.
- Lahey Hospital, Burlington, MA, USA.
- Midstate Radiology Associates, Meriden, CT, USA.
- Lank Center for Genitourinary Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
Zitieren
APA
Robertson, M. S., Wang, Y., Cheng, S., Park, H., Glomski, S., Harshman, L. C., Pace, A., Kilar, J., Flynn, M., Gilbert, L., Choudhury, A. D., & Jacene, H. (2024). Quantification of normal bone and osseous metastases in castration-resistant prostate cancer using SPECT/CT with xSPECT Quant: prospective imaging sub-study of a phase 2 clinical trial investigating the combination of pembrolizumab plus radium-223 compared to radium-223 alone. La radiologia medica. https://doi.org/10.1007/s11547-024-01931-7
Vancouver
Robertson MS, Wang Y, Cheng S, Park H, Glomski S, Harshman LC, et al. Quantification of normal bone and osseous metastases in castration-resistant prostate cancer using SPECT/CT with xSPECT Quant: prospective imaging sub-study of a phase 2 clinical trial investigating the combination of pembrolizumab plus radium-223 compared to radium-223 alone. La radiologia medica. 2024. doi:10.1007/s11547-024-01931-7
BibTeX
@article{Robertson2024,
author = {Robertson, Matthew S and Wang, Yating and Cheng, SuChun and Park, Hyesun and Glomski, Shahar and Harshman, Lauren C and Pace, Amanda and Kilar, Jacqueline and Flynn, Meredith and Gilbert, Lauren and Choudhury, Atish D and Jacene, Heather},
title = {Quantification of normal bone and osseous metastases in castration-resistant prostate cancer using SPECT/CT with xSPECT Quant: prospective imaging sub-study of a phase 2 clinical trial investigating the combination of pembrolizumab plus radium-223 compared to radium-223 alone},
journal = {La radiologia medica},
year = {2024},
doi = {10.1007/s11547-024-01931-7}
}
EUVIMED